tracken
PTC Therapeutics, Inc. Aktie News
Neutral
Seeking Alpha
●
6 Tage alt
PTC Therapeutics, Inc. (PTCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral
PRNewsWire
●
6 Tage alt
– Strong Sephience™ (sepiapterin) launch continues with unaudited Q4 global revenue of $92.5M – – Unaudited 2025 total product and royalty revenue of approximately $823M, exceeding guidance – – 2026 product revenue guidance of $700 – 800M, representing 19 – 36% year-over-year growth – – Strong cash position of approximately $1.94B as of December 31 – WARREN, N.J., Jan. 12, 2026 /PRNewswire/ -- ...
Neutral
PRNewsWire
●
9 Tage alt
WARREN, N.J., Jan. 8, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 2, 2026, the company approved 300 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to a new non-executive employee.
Neutral
PRNewsWire
●
27 Tage alt
– Indication includes all ages and the full spectrum of disease severity – – First Japan product approval for PTC – WARREN, N.J. , Dec. 22, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that Sephience™ (sepiapterin) has been approved by the Japanese Ministry of Health, Labor and Welfare (MHLW) for the treatment of children and adults living with phenylketonuria (PKU).
Neutral
PRNewsWire
●
29 Tage alt
WARREN, N.J. , Dec. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 16, 2025, the company approved non-statutory stock options to purchase an aggregate of 3,825 shares of its common stock and 4,385 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to five new employees.
Neutral
PRNewsWire
●
etwa ein Monat alt
WARREN, N.J. , Dec. 18, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B.
Neutral
Seeking Alpha
●
etwa ein Monat alt
PTC Therapeutics, Inc. (PTCT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Neutral
The Motley Fool
●
etwa 2 Monate alt
California-based Palo Alto Investors increased its stake in PTCT by 456,144 shares in the third quarter, adding approximately $33.1 million in value. The change represents approximately 4.4% of reportable assets under management.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
